Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Other antineoplastic Drugs >  Ustekinumab

Ustekinumab

Basic information Safety Supplier Related

Ustekinumab Basic information

Product Name:
Ustekinumab
Synonyms:
  • ustekinumab
  • Ustekinumab USP/EP/BP
  • Research Grade Ustekinumab(DHD84001)
  • inhibit,Interleukin Related,Inhibitor,Ustekinumab
  • Ustekinuma
CAS:
815610-63-0
MW:
0
Mol File:
Mol File
More
Less

Ustekinumab Chemical Properties

storage temp. 
Store at -80°C
solubility 
Soluble in DMSO
form 
Liquid
color 
Colorless to light yellow
More
Less

Ustekinumab Usage And Synthesis

Description

Psoriasis is a chronic inflammatory skin disorder that affects approximately 2-3% of the world’s population. The most common form of the disease is plaque psoriasis, which is a result of dysregulated cell growth. Conventional treatment options for psoriasis include topical corticosteroids, phototherapy, and systemic drugs (oral retinoids, cyclosporine, and MTX), but all of these therapies have limitations. Ustekinumab is the latest biologic to be approved for the treatment of plaque psoriasis. It is a human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit used by both the interleukin-12 (IL-12) and interleukin-23 (IL-23) cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as NK cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab is shown to disrupt IL12- and IL-23-mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12?1. Ustekinumab is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Adverse events associated with the use of ustekinumab included nasopharyngitis, upper respiratory tract infection, headache, fatigue, and diarrhea.

Originator

Medarex (US)

Uses

Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis or certain bowel conditions.

brand name

Stelara

UstekinumabSupplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Shanghai Fuhe Chemistry Technology Co., Ltd.
Tel
0086-21-67651709
Email
cfx759@hotmail.com
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Email
buy@fortunachem.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Email
sales@sunlidabio.com